Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design.

Jaclyn CarberryMark C PetrieMatthew M Y LeeKatriona BrooksbankRoss T CampbellRichard GoodPardeep S JhundPeter KellmanNinian N LangKenneth MangionPatrick B MarkAlex McConnachieJohn J V McMurrayBarbara MeyerVanessa OrchardAadil ShaukatStuart WatkinsPaul WelshNaveed SattarColin BerryKieran F Docherty

Published in: ESC heart failure (2024)

EMPRESS-MI will assess the effect of the SGLT2 inhibitor empagliflozin on cardiac remodelling in patients with left ventricular systolic dysfunction after an acute MI.

Keyphrases

left ventricular
heart failure
hypertrophic cardiomyopathy
liver failure
cardiac resynchronization therapy
acute myocardial infarction
multiple sclerosis
left atrial
aortic stenosis
mitral valve
blood pressure
oxidative stress
drug induced
respiratory failure
emergency department
intensive care unit
adverse drug